title: Clinical outcome in patients with small-intestinal non-Hodgkin lymphoma.
abstract: The clinical features and outcome of small intestinal lymphoma remain unclear. We retrospectively analyzed 23 patients who had non-Hodgkin lymphoma with a small intestinal lesion. With a median follow-up of 37 months, the 5-year overall survival and failure-free survival (FFS) were 64% and 60%, respectively. In a univariate analysis, a worse performance status at the start of treatment and the occurrence of abdominal symptoms or perforation during treatment were associated with poor survival. Perforation often resulted in a dismal prognosis in patients with uncontrollable lymphoma, but not in patients with lymphoma in remission. The role of surgery in small intestinal lymphoma remains equivocal. In the current study, surgery before other therapies favorably influenced FFS, and all patients who underwent complete resection of the small intestinal lesion had extremely favorable results. Further studies are warranted to establish optimal therapeutic strategies.
authors: Division of Hematology, Department of Internal medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
authors: Shinichi
authors: S
authors: Kako
authors: Kumi
authors: K
authors: Oshima
authors: Miki
authors: M
authors: Sato
authors: Kiriko
authors: K
authors: Terasako
authors: Shinya
authors: S
authors: Okuda
authors: Hideki
authors: H
authors: Nakasone
authors: Rie
authors: R
authors: Yamazaki
authors: Yukie
authors: Y
authors: Tanaka
authors: Aki
authors: A
authors: Tanihara
authors: Yutaka
authors: Y
authors: Kawamura
authors: Hirokazu
authors: H
authors: Kiyosaki
authors: Takakazu
authors: T
authors: Higuchi
authors: Junji
authors: J
authors: Nishida
authors: Fumio
authors: F
authors: Konishi
authors: Yoshinobu
authors: Y
authors: Kanda
mesh_terms: D015746:Abdominal Pain / Q000209:etiology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006801:Humans; D007078:Ileal Neoplasms / Q000150:complications / Q000188:drug therapy / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D007415:Intestinal Obstruction / Q000209:etiology; D007416:Intestinal Perforation / Q000209:etiology; D007564:Japan / Q000453:epidemiology; D007580:Jejunal Neoplasms / Q000150:complications / Q000188:drug therapy / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome